Economic Evaluation of Cancer Drugs

The first book on the design and analysis of not only clinical trials but also how observational non-interventional data using clinical data is applied to economic evaluation and re-imbursement in the context of Cancer. This book is a non technical exposition of economic evaluation and no knowledge of advanced statistical methods is assumed.

Iftekhar Khan is a medical statistician and health economist and a lead statistician at Oxford Unviersity's Center for Statistics in Medicine. Professor Khan is also a Senior Research Fellow in Health Economics at University of Warwick and is a Senior Statistical Assessor within the Licensing Division of the UK Medicine and Health Regulation Agency. Ralph Crott is a former professor in Pharmacoeconomics at the University of Montreal in Quebec, Canada and former head of the EORTC Health Economics Unit and former senior health economist at the Belgian HTA organization. Zahid Bashir has over twelve years experience working in the pharmaceutical industry in medical affairs and oncology drug development where he is involved in the design and execution of oncology clinical trials and development of reimbursement dossiers for HTA submission.

Preface, Acknowledgments, Acronyms and Abbreviations, 1 Introduction to Cancer 2 Important Outcomes for Economic Evaluation in Cancer Studies 3 Health-Related Quality of Life for Cost-Effectiveness 4 Introductory Statistical Methods for Economic Evaluation in Cancer 5 Collecting and Analysis of Costs from Cancer Studies 6 Designing Cost-Effectiveness into Cancer Trials 7 Models for Economic Evaluation of Cancer 8 Real-World Data in Cost-Effectiveness 9 Reporting and Interpreting Results of Cost-Effectiveness Analyses from Cancer Trials 10 Factors Predictive of HTA Success and the Global Landscape